top of page

Scancell intends to develop SCIB2 for treatment of lung cancer

Cancer immunotherapies developer Scancell said it intends to develop its SCIB2 ImmunoBody for the treatment of non-small-cell lung cancer and is preparing clinical trials in line with this goal.

SCIB2 will be studied in combination with a checkpoint inhibitor and follow the publication of data in journal OncoImmunology, which showed the drug demonstrated potent anti-tumour immunity.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page